Business Description
Tempest Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US87978U1088
Description
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.9 | |||||
| Equity-to-Asset | 0.52 | |||||
| Debt-to-Equity | 0.77 | |||||
| Debt-to-EBITDA | -0.75 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 14.2 | |||||
| 3-Year EPS without NRI Growth Rate | 12.9 | |||||
| 3-Year FCF Growth Rate | 14.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.9 | |||||
| 9-Day RSI | 49.29 | |||||
| 14-Day RSI | 48.42 | |||||
| 6-1 Month Momentum % | 43.2 | |||||
| 12-1 Month Momentum % | 156.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.29 | |||||
| Quick Ratio | 4.29 | |||||
| Cash Ratio | 4.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -49.2 | |||||
| Shareholder Yield % | -46.69 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -247.13 | |||||
| ROA % | -77.71 | |||||
| ROIC % | -175.57 | |||||
| ROC (Joel Greenblatt) % | -238.29 | |||||
| ROCE % | -93.79 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.04 | |||||
| Price-to-Tangible-Book | 3.06 | |||||
| EV-to-EBIT | -2.26 | |||||
| EV-to-Forward-EBIT | -1.7 | |||||
| EV-to-EBITDA | -2.29 | |||||
| EV-to-Forward-EBITDA | -1.7 | |||||
| EV-to-FCF | -2.3 | |||||
| Price-to-Net-Current-Asset-Value | 5.28 | |||||
| Price-to-Net-Cash | 5.65 | |||||
| Earnings Yield (Greenblatt) % | -44.25 | |||||
| FCF Yield % | -33.58 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tempest Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.774 | ||
| Beta | 0 | ||
| Volatility % | 1262.41 | ||
| 14-Day RSI | 48.42 | ||
| 14-Day ATR (€) | 0.187931 | ||
| 20-Day SMA (€) | 3.2814 | ||
| 12-1 Month Momentum % | 156.56 | ||
| 52-Week Range (€) | 0.173 - 8.2 | ||
| Shares Outstanding (Mil) | 22.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tempest Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tempest Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tempest Therapeutics Inc Frequently Asked Questions
What is Tempest Therapeutics Inc(FRA:3OS)'s stock price today?
The current price of FRA:3OS is €3.28. The 52 week high of FRA:3OS is €8.20 and 52 week low is €0.17.
When is next earnings date of Tempest Therapeutics Inc(FRA:3OS)?
The next earnings date of Tempest Therapeutics Inc(FRA:3OS) is 2024-05-31 Est..
Does Tempest Therapeutics Inc(FRA:3OS) pay dividends? If so, how much?
Tempest Therapeutics Inc(FRA:3OS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers